Erasca (ERAS) investor relations material

Executive summary

• Focused on developing therapies for RAS/MAPK pathway-driven cancers, with two clinical-stage programs (ERAS-0015 and ERAS-4001) and a discovery-stage antibody program (ERAS-12).

• Announced positive preliminary Phase 1 data for ERAS-0015, showing robust efficacy and favorable safety in RAS-mutant solid tumors, including strong monotherapy efficacy in 2L+ KRAS G12X pancreatic cancer and ongoing combination therapy advancement.

• ERAS-0015 is advancing toward three potentially registration-enabling trials in pancreatic and lung cancers, with additional data expected in H1 2027.

• Terminated development of naporafenib to prioritize RAS-targeting franchise.

• Raised significant capital through underwritten offerings, with $384.3 million in cash, cash equivalents, and marketable securities as of June 30, 2026, and $593.5 million to $632 million in net proceeds from a July 2026 offering.

Financial highlights

• Net loss of $44.1 million for Q2 2026, up from $33.9 million in Q2 2025; net loss of $227.5 million for the first half of 2026, up from $64.8 million in the prior year period.

• Research and development expenses rose to $35.9 million in Q2 2026 (from $21.2 million) and $63.2 million for the first half (from $47.1 million), driven by increased clinical and preclinical activity.

• In-process R&D expense of $150.0 million in H1 2026 due to a license territory expansion payment.

• Cash, cash equivalents, and marketable securities totaled $384.3 million as of June 30, 2026, up from $341.8 million at year-end 2025.

• G&A expenses increased to $11.7 million from $9.5 million year-over-year.

Outlook and guidance

• Cash and marketable securities, plus July 2026 offering proceeds, expected to fund operations for at least the next twelve months and achieve key clinical milestones, including multiple pivotal trials and data readouts through 2027.

• Anticipates Phase 1 monotherapy and combination data for ERAS-0015 in H1 2027 and Phase 1 data for ERAS-4001 in H2 2026, with expansion and combination cohorts planned for 2027.